Core Viewpoint - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. has signed a technology development cooperation agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. to advance the BIOS-0629 project, focusing on the treatment of solid tumors in the Greater China region [1][2]. Group 1: Project Overview - The BIOS-0629 project is an in-house developed product by Baicheng Pharmaceutical, targeting solid tumor indications and currently in the PCC (Preclinical Candidate) stage [2]. - The cooperation is limited to the Greater China region, including mainland China and Hong Kong, Macau, and Taiwan, while other rights remain with Baicheng Pharmaceutical [2]. Group 2: Cooperation Details - The agreement specifies clear roles: Baicheng Pharmaceutical will handle research, clinical trials, and registration, while Zhongshen Innovative will manage development, production, sales, and market expansion in the Greater China region [3]. - The total transaction amount is set at 300 million yuan, with milestone payments made by Zhongshen Innovative based on research progress, and Baicheng Pharmaceutical will receive a 10% commission on sales after the product is launched in the Greater China region [3]. Group 3: Counterparty Background - Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. was established on August 5, 2025, with a registered capital of 10.755 million yuan, focusing on medical research and technology development [4]. - The company has a good credit status and strong payment capability, ensuring its ability to fulfill contractual obligations [4]. Group 4: Impact on Company - The signing and implementation of the agreement are expected to positively impact Baicheng Pharmaceutical's future operating performance, enhancing its pipeline in the oncology treatment sector and improving profitability [5]. - The company emphasizes that the contract will not adversely affect its business independence, and it will not become dependent on the counterparty for its main operations [5].
百诚医药就BIOS-0629项目签署合作协议 获3亿元里程碑款并享10%销售提成